Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant docetaxel plus hormone therapy for high-risk localized prostate cancer
2007-003137-17Phase 4Active
- Sponsor
- Grupo de Investigación Clínica en Oncología Médica
- Start
- Jun 2008
- Modality
- Small Molecules, Peptides, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of docetaxel, triptorelin, goserelin, leuprolide and bicalutamide in prostate cancer (PCa), sponsored by Grupo de Investigación Clínica en Oncología Médica. Primary endpoint: Pathologic response. Started Jun 2008; status: active.
02
Drugs
docetaxeltriptorelingoserelinleuprolidebicalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2007-003137-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003137-17.